We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
J&J's Darzalex Subcutaneous Version Gets Approval in Europe
Read MoreHide Full Article
Janssen, a subsidiary of Johnson & Johnson (JNJ - Free Report) , announced that the European Commission has granted marketing authorization for the subcutaneous (“SC”) formulation of blood cancer drug, Darzalex (daratumumab) as a treatment for multiple myeloma (MM).
The approval applies to all current MM indications of Darzalex in frontline and relapsed/refractory settings. Patients currently on Darzalex intravenous formulation (“IV”) can switch to the SC formulation.
With the approval to the SC formulation of Darzalex, the administration time will be significantly reduced to three to five minutes compared to hours for IV formulation.
The SC formulation of Darzalex was approved by the FDA last month for similar indications, which is available as Darzalex Faspro. The SC formulation is developed using Halozyme’s (HALO - Free Report) ENHANZE technology.
Please note that an intravenous formulation of Darzalex is approved as monotherapy as well as in combination with other drugs for treating MM patients in first-line as well as second or later-line settings.
The approval for subcutaneous formulation was based on data from the phase III COLUMBA study as well as phase II PLEIADES study. Data from both studies have shown that Darzalex SC had consistent overall response rate and a similar safety profile compared to Darzalex IV in patients with relapsed or refractory MM.
Shares of J&J have increased 0.6% year to date against the industry’s decline of 1.6%.
Darzalex is a key drug in J&J’s portfolio. Sales of the drug rose 49% to $937 million in the first quarter of 2020. In the United States, market growth and market share gains drove sales. Outside U.S. markets, increased penetration and share gains boosted sales.
Meanwhile, Darzalex is being evaluated in a comprehensive clinical development program across a range of treatment settings in multiple myeloma, such as in frontline and relapsed settings. These include combination studies with other cancer drugs like Roche Holding AG’s (RHHBY - Free Report) Tecentriq, Bristol-Myers’ (BMY - Free Report) Opdivo and Amgen’s Kyprolis.
Would you like to see the updated picks from our best market-beating strategies? From 2017 through 2019, while the S&P 500 gained and impressive +53.6%, five of our strategies returned +65.8%, +97.1%, +118.0%, +175.7% and even +186.7%.
This outperformance has not just been a recent phenomenon. From 2000 – 2019, while the S&P averaged +6.0% per year, our top strategies averaged up to +54.7% per year.
Image: Bigstock
J&J's Darzalex Subcutaneous Version Gets Approval in Europe
Janssen, a subsidiary of Johnson & Johnson (JNJ - Free Report) , announced that the European Commission has granted marketing authorization for the subcutaneous (“SC”) formulation of blood cancer drug, Darzalex (daratumumab) as a treatment for multiple myeloma (MM).
The approval applies to all current MM indications of Darzalex in frontline and relapsed/refractory settings. Patients currently on Darzalex intravenous formulation (“IV”) can switch to the SC formulation.
With the approval to the SC formulation of Darzalex, the administration time will be significantly reduced to three to five minutes compared to hours for IV formulation.
The SC formulation of Darzalex was approved by the FDA last month for similar indications, which is available as Darzalex Faspro. The SC formulation is developed using Halozyme’s (HALO - Free Report) ENHANZE technology.
Please note that an intravenous formulation of Darzalex is approved as monotherapy as well as in combination with other drugs for treating MM patients in first-line as well as second or later-line settings.
The approval for subcutaneous formulation was based on data from the phase III COLUMBA study as well as phase II PLEIADES study. Data from both studies have shown that Darzalex SC had consistent overall response rate and a similar safety profile compared to Darzalex IV in patients with relapsed or refractory MM.
Shares of J&J have increased 0.6% year to date against the industry’s decline of 1.6%.
Darzalex is a key drug in J&J’s portfolio. Sales of the drug rose 49% to $937 million in the first quarter of 2020. In the United States, market growth and market share gains drove sales. Outside U.S. markets, increased penetration and share gains boosted sales.
Meanwhile, Darzalex is being evaluated in a comprehensive clinical development program across a range of treatment settings in multiple myeloma, such as in frontline and relapsed settings. These include combination studies with other cancer drugs like Roche Holding AG’s (RHHBY - Free Report) Tecentriq, Bristol-Myers’ (BMY - Free Report) Opdivo and Amgen’s Kyprolis.
Johnson Johnson Price
Johnson Johnson price | Johnson Johnson Quote
Zacks Rank
J&J currently carries a Zacks Rank #4 (Sell).
You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Today's Best Stocks from Zacks
Would you like to see the updated picks from our best market-beating strategies? From 2017 through 2019, while the S&P 500 gained and impressive +53.6%, five of our strategies returned +65.8%, +97.1%, +118.0%, +175.7% and even +186.7%.
This outperformance has not just been a recent phenomenon. From 2000 – 2019, while the S&P averaged +6.0% per year, our top strategies averaged up to +54.7% per year.
See their latest picks free >>